Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2004

01-07-2004 | Report

Identification of HER2/neu-Derived Peptides Capable of Inducing both Cellular and Humoral Immune Responses in HLA-A24 Positive Breast Cancer Patients

Authors: Koichi Azuma, Shigeki Shichijo, Hiroki Shomura, Satoko Matsueda, Teruhiko Fujii, Kyogo Itoh

Published in: Breast Cancer Research and Treatment | Issue 1/2004

Login to get access
Metadata
Title
Identification of HER2/neu-Derived Peptides Capable of Inducing both Cellular and Humoral Immune Responses in HLA-A24 Positive Breast Cancer Patients
Authors
Koichi Azuma
Shigeki Shichijo
Hiroki Shomura
Satoko Matsueda
Teruhiko Fujii
Kyogo Itoh
Publication date
01-07-2004
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/2004
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/B:BREA.0000032920.95410.63

Other articles of this Issue 1/2004

Breast Cancer Research and Treatment 1/2004 Go to the issue

OriginalPaper

Differential Gene Expression of TGFβ Inducible Early Gene (TIEG), Smad7, Smad2 and Bard1 in Normal and Malignant Breast Tissue

Report

The Role of MRI in Invasive Lobular Carcinoma

Erratum

Use of Complementary and Alternative Medicine by Chinese Women with Breast Cancer

Instructions for Authors

Instructions for Authors

OriginalPaper

Growth and EGFR Regulation in Breast Cancer Cells by Vitamin D and Retinoid Compounds

OriginalPaper

Prognostic and Predictive Impact of the HER-2/neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits